Physician profile
Simon Behar
NPI 1982706958
$17,800.02
in general payments reported to CMS, 2019-2025
44 companies · $3,512 in 2025
The $3,512 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,891 · 2020: $1,177 · 2021: $2,779 · 2022: $3,248 · 2023: $2,624 · 2024: $2,568 · 2025: $3,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,507 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,507.01 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,961.46 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,379.08 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $2,256.36 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $1,553.53 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $767.65 | 2021-2023 | Zeposia |
| Genzyme Corporation | $732.31 | 2022-2025 | |
| Gilead Sciences, INC. | $682.25 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $589.29 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Redhill Biopharma INC. | $553.21 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $517.30 | 2019-2024 | Linzess |
| Ardelyx, INC. | $474.51 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $391.99 | 2021-2023 | |
| Daiichi Sankyo INC. | $344.32 | 2019-2023 | Injectafer |
| Celltrion USA INC. | $321.09 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $297.67 | 2024-2025 | Omvoh |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $262.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $262.25 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $239.14 | 2022-2025 | Dupixent |
| Pfizer INC. | $238.28 | 2023-2025 | |
| Novo Nordisk INC | $230.73 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $205.42 | 2024-2025 | Iqirvo |
| Alfasigma USA, INC. | $185.32 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $174.36 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $171.12 | 2022-2025 | |
| Vivus LLC | $137.59 | 2021-2025 | Qsymia, Pancreaze |
| Merck Sharp & Dohme LLC | $116.72 | 2019-2024 | Dificid |
| Evoke Pharma, INC. | $96.61 | 2023-2025 | Gimoti |
| Braintree Laboratories, INC. | $84.07 | 2019-2024 | Suflave |
| Ferring Pharmaceuticals INC. | $82.92 | 2019-2025 | Rebyota |
| Allergan, INC. | $82.34 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $75.69 | 2021 | |
| Exact Sciences Corporation | $43.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pharmacosmos Therapeutics INC. | $42.46 | 2023-2024 | Monoferric |
| Romark Laboratories, Lc | $31.36 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $30.81 | 2021 | |
| Boston Scientific Corporation | $30.59 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $29.51 | 2022-2023 | Andexxa |
| Alnylam Pharmaceuticals INC. | $22.15 | 2024 | Givlaari |
| Fujifilm Healthcare Americas Corporation | $20.79 | 2023 | Fujifilm |
| Ascendis Pharma Endocrinology INC | $19.79 | 2024 | |
| Covidien Lp | $18.32 | 2019 | |
| Shire North American Group INC | $16.58 | 2019 | |
| Ucb, INC. | $15.49 | 2019 | |
| Pentax of America, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Behar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.